학술논문
The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity
Document Type
Article
Author
Source
In: Nature Communications . (Nature Communications, December 2022, 13(1))
Subject
Language
English
ISSN
20411723